TrialBMC pharmacology & toxicology2022

A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients.

Reza Safaei Nodehi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.